Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
HSTC
HST Global
$0.94
+44.6%
$0.72
$0.10
$1.15
N/A-1.062,475 shs1,000 shs
NSPX
Inspyr Therapeutics
$0.00
$0.00
$0.07
$1.47M-17.3313.19 million shs29.64 million shs
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
$5.47
$5.47
$5.47
$352.00
$127.45M2.46279 shsN/A
Targeted Medical Pharma, Inc. stock logo
TRGM
Targeted Medical Pharma
$0.00
$0.00
$0.00
N/AN/AN/AN/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
HSTC
HST Global
0.00%-41.96%-23.53%+29.99%+550.00%
NSPX
Inspyr Therapeutics
0.00%0.00%0.00%0.00%0.00%
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
0.00%0.00%0.00%0.00%0.00%
Targeted Medical Pharma, Inc. stock logo
TRGM
Targeted Medical Pharma
0.00%0.00%0.00%0.00%-83.33%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
HSTC
HST Global
N/AN/AN/AN/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Targeted Medical Pharma, Inc. stock logo
TRGM
Targeted Medical Pharma
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
HSTC
HST Global
N/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/AN/AN/AN/A
Targeted Medical Pharma, Inc. stock logo
TRGM
Targeted Medical Pharma
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
HSTC
HST Global
N/AN/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
$36.55M3.49N/AN/A($67.63) per share-0.08
Targeted Medical Pharma, Inc. stock logo
TRGM
Targeted Medical Pharma
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
HSTC
HST Global
-$150K-$0.04N/AN/AN/AN/A-9,797.01%N/A
NSPX
Inspyr Therapeutics
-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
-$150.73MN/A0.00N/A-894.02%-3,350.55%-67.76%N/A
Targeted Medical Pharma, Inc. stock logo
TRGM
Targeted Medical Pharma
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest TRGM, HSTC, PFSCF, and NSPX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/5/2024Q4 2023
HSTC
HST Global
N/A-$0.01-$0.01-$0.01N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
HSTC
HST Global
N/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/AN/AN/AN/AN/A
Targeted Medical Pharma, Inc. stock logo
TRGM
Targeted Medical Pharma
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
HSTC
HST Global
N/AN/AN/A
NSPX
Inspyr Therapeutics
N/A
0.09
0.09
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/A
0.95
0.71
Targeted Medical Pharma, Inc. stock logo
TRGM
Targeted Medical Pharma
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
HSTC
HST Global
N/A
NSPX
Inspyr Therapeutics
0.02%
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
0.10%
Targeted Medical Pharma, Inc. stock logo
TRGM
Targeted Medical Pharma
N/A

Insider Ownership

CompanyInsider Ownership
HSTC
HST Global
65.82%
NSPX
Inspyr Therapeutics
0.02%
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
N/A
Targeted Medical Pharma, Inc. stock logo
TRGM
Targeted Medical Pharma
69.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
HSTC
HST Global
1N/AN/ANot Optionable
NSPX
Inspyr Therapeutics
1543.15 millionN/ANot Optionable
ProMetic Life Sciences Inc. stock logo
PFSCF
ProMetic Life Sciences
48723.31 millionN/ANot Optionable
Targeted Medical Pharma, Inc. stock logo
TRGM
Targeted Medical Pharma
30N/AN/ANot Optionable

TRGM, HSTC, PFSCF, and NSPX Headlines

No headlines for this company have been tracked by MarketBeat.com

Company Descriptions

HST Global

OTCMKTS:HSTC
HST Global, Inc., an integrated health and wellness biotechnology company, develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer in the United States and internationally. The company also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancers and other life-threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.

Inspyr Therapeutics

OTCMKTS:NSPX
Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.
ProMetic Life Sciences logo

ProMetic Life Sciences

OTCMKTS:PFSCF
Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.
Targeted Medical Pharma logo

Targeted Medical Pharma

OTCMKTS:TRGM
Targeted Medical Pharma, Inc., a specialty pharmaceutical company, doing business as Physician Therapeutics, develops and commercializes amino acid based medications to physicians, pharmacies, and patients in the United States. It offers a line of patented amino acid based medical food products, dietary supplements, and generic drugs primarily for the treatment of metabolic syndrome/obesity; sleep disorders associated with anxiety; hypertension; viral infections; cognitive disorders/fatigue; sleep disorders associated with depression, fibromyalgia, and PTSD; pain disorders and inflammatory conditions/fibromyalgia; osteoarthritis and joint disorders; and peripheral neuropathy. The company also provides a proprietary billing process and supporting software (PDRx) that facilitates physician dispensing; provides inventory control; and assists regulatory reporting. In addition, it offers billing and collection services relating to its products on behalf of dispensing physician clients to private insurance and workers' compensation insurance. Targeted Medical Pharma, Inc. distributes its products through a network of distributors and an internal sales force that sells products directly to dispensing physician clients. The company was formerly known as Targeted Medical Foods and changed its name to Targeted Medical Pharma, Inc. in 2006. Targeted Medical Pharma, Inc. was founded in 1996 and is headquartered in Los Angeles, California.